1. Home
  2. MDXH

as of 11-06-2026 3:55pm EST

$0.16
+$0.01
+6.16%
Stocks Nasdaq

MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.

Founded: 2003 Country:
Belgium
Belgium
Employees: 364 City: N/A
Market Cap: 15.0M IPO Year: 2021
Target Price: $0.83 AVG Volume (30 days): 1.7M
Analyst Decision: Hold Number of Analysts: 6
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: N/A EPS Growth: N/A
52 Week Low/High: $0.15 - $4.63 Next Earning Date: 11-12-2026
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): 6.81% Revenue Growth (next year): 13.37%
P/E Ratio: N/A Index: N/A
Free Cash Flow: N/A FCF Growth: N/A

Stock Insider Trading Activity of MDxHealth SA (MDXH)

Buy
MDXH Aug 13, 2026

Avg Cost/Share

$0.45

Shares

2,202,643

Total Value

$999,999.92

Owned After

6,903,100

SEC Form 4

Share on Social Networks: